Oxford Biomedica (NASDAQ:OXBDF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Shares of Oxford Biomedica (OXBDF) opened at 0.11 on Wednesday. The firm’s 50-day moving average price is $0.12 and its 200 day moving average price is $0.12. The company’s market cap is $339.71 million. Oxford Biomedica has a 52 week low of $0.04 and a 52 week high of $0.15.

COPYRIGHT VIOLATION WARNING: “Oxford Biomedica (OXBDF) Rating Lowered to Hold at Zacks Investment Research” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://theolympiareport.com/2017/11/01/oxford-biomedica-oxbdf-rating-lowered-to-hold-at-zacks-investment-research.html.

Oxford Biomedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with Analyst Ratings Network's FREE daily email newsletter.